Page 2530 - Williams Hematology ( PDFDrive )

2501
2500 Index Index 2501

in deep vein thrombosis, 2269–2270 Urticaria pigmentosa, 973–974, 974f, 977 fibrinolytic assembly and, 1975–1976,
fetal, 854, 855f UTAF1, 228t 1975f
spleen, 850f, 851f Uterus, primary lymphomas in, 1582 fibrinolytic function in, 1974–1975, 1974t,
Ultraviolet light therapy. See Phototherapy; UTX, 1736, 1736t 1975f
Psoralen plus ultraviolet A (PUVA) UTY, 414 folic acid deficiency and, 598–599
Umbilical cord blood, 102, 357, 358 homocysteine in, 1976
Umbilical stump, bleeding from, 1988 V lipoprotein(a) in, 1976
UNC93B1, 296, 296f V1-type receptor, 1879 peripheral vascular disease, 2240, 2316–
Unexplained anemia, 136 Vaccine therapy 2317
UNG (uracil DNA glycosylase), 1169, 1214t, for acute myelogenous leukemia, 1404 sickle cell disease and, 765
1215 advantages, 421 Vascular endothelial growth factor (VEGF)
Unsaturated or latent iron-binding capacity antigen discovery for, 421, 422t in α-granules, 1843, 1844f
(UIBC), 634 assays of efficacy, 422, 423t in chronic myelogenous leukemia, 1449
Unstable angina, 2296 B-cell antigen-receptor, 423, 423f, 424f in platelets, 1848
Unstable hemoglobins, 781–782 clinical trial design, 422 in preeclampsia, 801, 2011–2012
u-PA (urokinase plasminogen activator), components, 421–422 Vascular endothelial growth factor (VEGF)
1973, 1973f, 1975 delivery strategies for, 422 inhibitors, 2263
Upregulation of costimulatory molecules for follicular lymphoma, 1648 Vascular endothelial growth factor (VEGF)
(UCM), 304 future directions, 424 receptor-1, 801
Upshaw-Schulman syndrome (congenital immunostimulants for enhanced efficacy Vascular fibrinolysis. See Fibrinolysis,
thrombotic thrombocytopenic of, 422 vascular
purpura), 2257–2258 impediments to, 423–424 Vascular purpuras, 2097–2109. See also
Uracil DNA glycosylase (UNG), 1169, 1214t, for myeloid leukemias, 423 specific conditions
1215 VACOP-B regimen, for primary mediastinal definition and diagnostic approach, 2097,
URAF1, 1346t large B-cell lymphoma, 1635 2098f
Ureaplasma urealyticum, 1212 Vacuolization, 23 nonpalpable, noninflammatory, round,
Uremia, 2083–2084 VAD regimen, for myeloma, 1750 2098t, 2107–2109
Ureter, primary lymphomas in, 1582 Valacyclovir palpable and nonpalpable inflammatory,
Urine as empiric therapy for infections, 386, 387t 2098t, 2102–2107
in primary myelofibrosis, 1327 prophylactic, 369, 389 palpable noninflammatory, 2097–2102,
protein electrophoresis, 1714 Valdecoxib, 2075 2098t
UROD. See Uroporphyrinogen decarboxylase Valganciclovir Vasculitis
(UROD) adverse effects, 1252 antineutrophil cytoplasmic antibody-
UROD, 905, 906 as empiric therapy for infections, 386, 387t associated, 2107, 2107f
Urokinase plasminogen activator (u-PA) prophylactic, 389 drug-induced, 2106, 2106f
comparison to other fibrinolytic agents, Valproic acid, 240 paraneoplastic, 2106
2291t VAMP, 1849, 1853 Vasoactive amines, 286t, 289
in fibrinolysis, 1975, 2304f, 2307 Vancomycin, 385, 387t Vasoactive intestinal peptide, 952
gene, 2306f Varicella zoster virus (VZV) infections, 370, Vasoactive substances, 2284f
in plasmin generation, 2311 384 Vasoocclusive crisis, in sickle cell disease,
production, 1973 Varices, blood loss from, 629 766–767, 768f
structure, 2304–2305t, 2306–2307 Variegate porphyria, 889, 890t, 891t, 904–905 Vasopressin, 1879. See also Desmopressin
Urokinase plasminogen activator receptor Vasa nervorum, 1746 (DDAVP)
(uPAR), 1973, 2305t, 2308–2309 Vascular anomalies, blood loss from, 629 VASP, 1833t, 1875, 1885
Uromodulin (Tamm-Horsfall mucoprotein), Vascular cell adhesion molecule (VCAM)-1 VCAM. See under Vascular cell adhesion
1744 atherosclerosis and, 2286 molecule
Uroporphyrinogen decarboxylase (UROD) endothelial inflammation and, 2283 V(D)J recombination, 1166f, 1168
functions, 895 in eosinophils, 950 Vegans, 602
porphyria cutanea tarda and, 905–906, 908 in hematopoietic stem cells, 261 VEGF. See Vascular endothelial growth factor
Uroporphyrinogen I synthase. See in inflammatory response, 1978 Velaglucerase alfa, for Gaucher disease,
Porphobilinogen (PBG) deaminase in leukocyte adhesion, 282–283 1127
Uroporphyrinogens, 891f, 893–894, 893f in sickle cell disease, 765 Vel blood group, 104, 2333t
Uroporphyrinogen synthase (UROS), 893, in T-cell adhesion, 1185 Vemurafenib
894–895 Vascular disease/injury. See also for Erdheim-Chester disease, 1111
UROS, 896 Cardiovascular disease for hairy cell leukemia, 1559
Ursodeoxycholic acid, 806 in antiphospholipid syndrome, 1976, 2237f for Langerhans cell histiocytosis, 1107

Kaushansky_index_p2393-2506.indd 2501 9/21/15 3:23 PM